# Allergy Therapeutics clinical trials: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials with Allergy Therapeutics as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Allergy Therapeutics: 27 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/allergy-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 17, 2026 | NCT07412990 | GRASS (Grass MATA MPL Real-world Assessment Study) | Allergy Therapeutics | Observational | Recruiting | Grass Pollen Allergy | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412990) |
| September 15, 2022 | NCT05540717 | Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen | Allergy Therapeutics | Phase 3 | Completed | Seasonal Allergic Rhinitis, Rhinoconjunctivitis | 555 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05540717) |
| July 27, 2022 | NCT05476497 | Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects | Allergy Therapeutics | Phase 1 | Active not recruiting | Peanut Allergy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05476497) |
| July 13, 2022 | NCT05455749 | Effect of holoBLG on Cat Allergic Patients | Allergy Therapeutics | Not applicable | Completed | Allergy to Cats, Allergic Rhinoconjunctivitis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05455749) |
| January 11, 2022 | NCT05186025 | Tyrosine Allergoid Paediatric and Adult Study | Allergy Therapeutics | Observational | Active not recruiting | Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05186025) |
| December 29, 2020 | NCT04687059 | An Exploratory Study of PQ Grass 27600 SU | Allergy Therapeutics | Phase 2/3 | Completed | Rhinitis, Allergic, Seasonal | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04687059) |
| May 15, 2020 | NCT04389034 | Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels | Allergy Therapeutics | Observational | Completed | Rhinitis, Allergic, Respiratory Tract Infections, Allergy, Allergic Asthma, Allergic Conjunctivitis | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04389034) |
| April 30, 2019 | NCT03931993 | A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL | Allergy Therapeutics | Phase 1 | Completed | Seasonal Allergic Rhinitis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03931993) |
| October 21, 2015 | NCT02582073 | Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™ | Allergy Therapeutics | Phase 2 | Completed | Seasonal Allergic Rhinitis | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02582073) |
| September 23, 2015 | NCT02557633 | A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL | Allergy Therapeutics | Phase 1 | Completed | Allergic Rhinitis | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02557633) |
| January 18, 2007 | NCT00423787 | Efficacy and Safety/Tolerability of Ragweed MATA MPL | Allergy Therapeutics | Phase 3 | Completed | Type I Hypersensitivity | 993 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00423787) |
| December 21, 2006 | NCT00414141 | Efficacy and Safety/Tolerability of Grass MATA MPL | Allergy Therapeutics | Phase 3 | Completed | Type I Hypersensitivity | 1,028 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00414141) |
| October 13, 2006 | NCT00387478 | Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis | Allergy Therapeutics | Phase 2 | Terminated | Type I Hypersensitivity | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00387478) |
| May 12, 2006 | NCT00325338 | Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00325338) |
| November 28, 2005 | NCT00258635 | Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00258635) |
| October 19, 2005 | NCT00241410 | Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen | Allergy Therapeutics | Phase 1 | Completed | Type I Hypersensitivity | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00241410) |
| August 23, 2005 | NCT00133159 | Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00133159) |
| August 23, 2005 | NCT00133146 | Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00133146) |
| July 12, 2005 | NCT00118625 | Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00118625) |
| July 12, 2005 | NCT00118612 | Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00118612) |
| June 29, 2005 | NCT00116285 | Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing | Allergy Therapeutics | Phase 1 | Completed | Type I Hypersensitivity | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00116285) |
| June 13, 2005 | NCT00113750 | Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00113750) |
| May 16, 2005 | NCT00110786 | Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy | Allergy Therapeutics | Phase 2 | Completed | Type I Hypersensitivity | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00110786) |
| May 4, 2005 | NCT00109759 | Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A) | Allergy Therapeutics | Phase 1 | Withdrawn | Type I Hypersensitivity | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00109759) |
| April 8, 2005 | NCT00107705 | Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing | Allergy Therapeutics | Phase 1 | Completed | Type I Hypersensitivity | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00107705) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Active not recruiting | 2 |
| Withdrawn | 1 |
| Recruiting | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypersensitivity | 20 |
| Hypersensitivity, Immediate | 17 |
| Rhinitis, Allergic, Seasonal | 5 |
| Rhinitis, Allergic | 2 |
| Conjunctivitis, Allergic | 2 |
| Peanut Hypersensitivity | 1 |
| Respiratory Tract Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
- [B2B environmental companies in the United States](https://specstream.ai/data/businesses/b2b-environmental-companies/united-states)
- [Moroccan restaurants in the United States](https://specstream.ai/data/businesses/moroccan-restaurants/united-states)
- [Cafes in the United States](https://specstream.ai/data/businesses/cafes/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
